Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 567

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 567
---
 |
| Diarrhoea                            |     | 0 (0)  |     | 1 (20) |     | 0 (0)   |     | 0 (0)  |     | 1 (17) |     | 0 (0)  |     | 0 (0)       |     | 1 (17)       |     | 3 (9)     |
| Blood bilirubin increased            |     | 0 (0)  |     | 0 (0)  |     | 1 (25)  |     | 0 (0)  |     | 0 (0)  |     | 0 (0)  |     | 1 (33)      |     | 0 (0)        |     | 2 (6)     |
| Myalgia                              |     | 1 (50) |     | 0 (0)  |     | 1 (25)  |     | 0(0)   |     | 0 (0)  |     | 0 (0)  |     | 0 (0)       |     | 0 (0)        |     | 2 (6)     |
| Pyrexia                              |     | 0 (0)  |     | 0 (0)  |     | 1 (25)  |     | 0(0)   |     | 1 (17) |     | 0 (0)  |     | 0 (0)       |     | 0 (0)        |     | 2 (6)     |

**Cohort B3 (300 mg KVA12123 IV Q2W + pembrolizumab 600mg Q6W) has enrolled 4 patients. These patients are still under assessment until the end of the DLT period and are not reflected in the table above . Furthermore, no evidence of CRS or associated cytokines including IL-6,TNFα & IL-10were detected. Figure 17. VISTA-101No CRS-relatedcytokine induction observed 361

Pharmacokinetics (PK) and Receptor Occupancy (RO)

PK is the study of how the body interacts with KVA12123 for the entire duration of exposure after administration. KVA12123 exhibited a greater than dose-proportional pharmacokinetic profile in drug exposure across all doses,